Elasmogen to present new data at the Nextgen Biomed Conference, 12-14th March 2025
Dr Obinna C Ubah ((Principal Scientist and Future Leaders Fellow(UKRI)) and Dr Euan Murray (Senior Scientist) will be presenting the latest data on our first-in-class soloMER drug conjugate, ELN28. Obinna's talk, "First-in-class Site-directed targeted soloMER Drug...
Elasmogen Presenting at World ADC Conference in London (3rd to 5th March 2025)
DR OBINNA C UBAH (Principal Scientist and Future Leaders Fellow (UKRI)) who leads our autoimmune inflammatory disease team is presenting new data on our lead first in class drug conjugate, ELN 28. His poster entitled, "Development and functional characterisation of...
Hands-on experience at Elasmogen for Harlaw Advanced Highers Students
It was fantastic to welcome and support Advanced Higher Biology pupils from Harlaw Academy again. The day began with some information about Elasmogen and drug discovery, followed by engaging discussions about two fundamental laboratory techniques and hands-on...
First in Class Bispecific Next Generation ADC targeting EGFR/ROR1 to progress into pre-clinical development
Almac Discovery, a research driven drug discovery company and member of the Almac Group, has announced the nomination of a new pre-clinical candidate molecule (ALM-401), a First in Class Bispecific Antibody Drug Conjugate (ADC) for the treatment of refractory lung...
2024 Impact Report: The Scottish National Investment Bank helps Elasmogen to develop next-generation therapeutic drugs
https://www.youtube.com/watch?v=YpcwHA7GG0w Hear from Elasmogen's CEO, Prof. Caroline Barelle, how The Scottish National Investment Bank helps to develop next-generation therapeutic drugs, with the potential to improve the health of people in Scotland and globally.
Harlaw Academy students visited Elasmogen
On 13th of November, as part of the Excelerate program, advanced higher biology students from Harlaw Academy visited Elasmogen. The students participated in interactive theory and practical sessions learning from Elasmogen’s scientists about fundamental ELISA and PCR...
Elasmogen has been announced as a finalist for the Deal & Dealmakers Awards
Insider.co.uk has announced today the shortlist for the Deal & Dealmakers Awards. Elasmogen is nominated for Early Stage Deal of the Year in partnership with RBC Brewin Dolphin. Please see here the link to the story.
Elasmogen team took a part in the regional event hosted by the BIA in collaboration with ONE
On 10th of May Elasmogen team took part in the regional event hosted by the BIA in collaboration with opportunity North East. The event took place at the new BioHub. Our principal scientist and program lead Dr Obinna Ubah was in the panel along with other life science...
Dr Jane Dancer named as the new Chair of Elasmogen Ltd
Elasmogen Ltd has announced the appointment of Jane Dancer as the Chair of the Board. Jane joined Elasmogen as a non-executive director in April 2022 on the back of new investment from BGF, The Bank and Scottish Enterprise who joined existing investors, Deepbridge...